(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

PROTEÍNAS QUE SE LIGAM A HER2, NKG2D E CD16

Em AnáliseInvention PatentPCT · US2018018771 Official document available

Application data

Number

112019017197

Type

Invention Patent

Filing

02/20/2018

Publication

04/14/2020

PCT

US2018018771

Patent grant document available

We have the complete official document for this filing, as published by INPI.

Access the document

Progress at the INPI

Technical opinion to answer
  1. Filing02/20/18
  2. Publication04/14/20
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

AlertaMarcas

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 06/09/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

DRAGONFLY THERAPEUTICS, INC.

US

See this company's full portfolio

Inventors

A. C. (pessoa física)

US

B. P. (pessoa física)

US

B. L. (pessoa física)

US

G. C. (pessoa física)

US

W. H. (pessoa física)

US

Technical data

Priority claims

US

62/461,146 · 02/20/2017

Abstract

São descritas proteínas de ligação multiespecíficas que se ligam a HER2, ao receptor NKG2D e CD16, bem como composições farmacêuticas e métodos terapêuticos úteis para o tratamento de câncer.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Conhecimento de parecer técnico

#7.1

06/09/2026

RPI 2892

Parecer de pré-exame

#6.23

07/09/2024

RPI 2792

Adição na publicação

#15.35

10/19/2021

RPI 2650

Notificação de entrada na fase nacional - PCT

#1.3

04/14/2020

RPI 2571

Alteração de dados cadastrais

#1.1

08/27/2019

RPI 2538

Related

Same category

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.